What is Entact Bio?
Entact Bio operates at the vanguard of precision medicine, specializing in the development of novel therapeutics that enhance protein function. By leveraging its proprietary Encompass platform, the company designs targeted small molecules, referred to as ENTACs, which are engineered to restore, relocate, or modulate protein activity within cellular environments. This approach effectively addresses previously undruggable pathways, offering a transformative solution for complex genetic disorders and chronic diseases. By focusing on the restoration of natural protein capabilities, Entact Bio is carving out a distinct market position as a leader in functional proteomics and targeted molecular therapy.
How much funding has Entact Bio raised?
Entact Bio has raised a total of $10M across 1 funding round:
Stock/Share Issuance
$10M
Stock/Share Issuance (2026): $10M, investors not publicly disclosed
Key Investors in Entact Bio
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Entact Bio?
Following this major enterprise-level funding, Entact Bio is poised to transition from early-stage discovery into more robust clinical development phases. The strategic allocation of this capital will likely prioritize the expansion of the Encompass platform's pipeline, enabling the company to scale its drug discovery efforts and advance lead candidates toward human trials. As the firm matures, the focus will shift toward establishing strategic partnerships with larger pharmaceutical entities to validate its therapeutic modalities. The current financial backing provides the necessary runway to navigate the complexities of regulatory approval and to solidify the company's intellectual property portfolio, ensuring long-term viability in the competitive landscape of biotechnology innovation.
See full Entact Bio company page
